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Background: Differentiation of atypical pathogens is important for community-acquired 
pneumonia (CAP). In this study, we compared sputum and nasopharyngeal swabs (NPS) 
for use in detection of Mycoplasma pneumoniae (MP), Chlamydophila pneumoniae (CP), 
and Legionella pneumophila (LP), using Seeplex PneumoBacter ACE Detection Assay 
(PneumoBacter; Seegene).
Methods: Sputum and NPS specimens were collected from patients in 15 hospitals. DNA 
was extracted from sputum using QIAamp DNA Stool Mini Kit (Qiagen) and from NPS us-
ing easyMAG (bioMérieux). Both types of specimens were evaluated by multiplex PCR us-
ing PneumoBacter. To determine the diagnostic performance of this assay, sputum sam-
ples were also tested using BD ProbeTec ET Atypical Pneumonia Assay (APA; Becton 
Dickinson).   
Results: Among 217 sputum and NPS, 20 (9.2%), 2 (0.9%), and 0 sputum were positive 
for MP, LP, and CP, respectively, whereas 8 (3.7%) NPS were positive for MP. The sputum 
APA test yielded 186, 206, and 204 interpretable results for MP, LP, and CP, respectively. 
Of these, 21 (11.3%) were positive for MP, 2 (1.0%) were positive for LP, and 0 samples 
were positive for CP. Compared to APA, the sensitivity and specificity of the sputum assay 
for MP were 95.2% and 100.0%, respectively, whereas for the NPS assay, these were 38.1% 
and 93.9%. Sputum testing was more sensitive than NPS testing (P=0.002). For LP and 
CP diagnosis, PneumoBacter and APA tests agreed 100%. 
Conclusions: Specimen type is crucial and sputum is preferred over NPS for simultane-
ous detection of MP, LP, and CP using multiplex PCR in CAP.
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INTRODUCTION
Mycoplasma pneumoniae (MP), Chlamydophila pneumoniae 
(CP), and Legionella pneumophila (LP) are the most common 
causes of atypical pneumonia [1, 2], which represents approxi-
mately 15% of all cases of community-acquired pneumonia 
(CAP) [2]. MP is second only to Streptococcus pneumoniae as 
the most common bacterial agent of CAP [3]. These atypical 
pathogens do not respond to β-lactam antimicrobial therapy, a 
commonly used empirical treatment for bacterial CAP [4]. There-
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fore, appropriate treatment of CAP requires the identification of 
the infecting pathogens [2, 5]. 
  Currently available methods for diagnosis of MP, CP, and LP 
include conventional culture, serology, and nucleic acid-based 
tests. Although culture and serological tests are traditionally rec-
ommended for confirmatory diagnosis of pneumonia caused by 
MP, CP, or LP, such tests are of limited clinical utility because of 
the fastidious growth characteristics of the pathogens and the 
long turnaround time of the tests [6, 7]. As nucleic acid-based 
tests are rapid, highly sensitive, and specific [8. 9], and as MP, 
CP, and LP rarely colonize the respiratory tract [10, 11], molecu-
lar diagnostic tests for these pathogens are expected to be im-
portant tools in the clinical laboratory [12]. Because it is difficult 
to differentiate among MP, CP, LP, and other pathogens that 
cause CAP when using clinical and conventional laboratory tests, 
simultaneous detection of all pathogens that cause CAP is desir-
able [2, 11].
  We recently had a chance to use Seeplex PneumoBacter ACE 
Detection Assays (PneumoBacter; Seegene, Seoul, Korea) to 
detect MP, CP, and LP for research. The appropriate specimen 
type for molecular diagnosis of atypical pneumonia remains 
controversial [9, 13, 14], and there have not yet been any reports 
describing the adequacy of different CAP specimen types for si-
multaneously detecting several atypical pathogens using multi-
plex PCR. 
  We therefore compared the detection of MP, CP, and LP in 
sputum and NPS samples using the PneumoBacter assay. The 
BD ProbeTec ET Atypical Pneumonia Assay (APA; Becton Dick-
inson, Sparks, MD, USA) was used as a control test. 
METHODS 
1. Patients and specimens
As part of a nationwide survey of CAP pathogens, sputum and 
NPS samples were collected from CAP patients diagnosed by 
previously reported criteria [3] at the time of initial assessment 
in 15 hospitals between May 2010 and February 2011. All speci-
mens were collected using the same protocol and collection de-
vices, which were distributed via the clinical microbiology labo-
ratory of the Asan Medical Center. Expectorated sputum speci-
mens were collected in sterile containers with screw caps, and 
NPS samples were obtained by use of flocked swabs and trans-
ported in universal transport medium (Copan Diagnostics, Co-
rona, Italy). All specimens were transported to the central labo-
ratory at 4°C within 24 hr of collection.
2. DNA extraction 
Sputum specimens (350 μL) were pre-treated with proteinase K, 
ASL buffer, and buffer AL, and incubated for 15 min at 70°C. 
DNA extraction was achieved using QIAamp DNA Stool Mini Kits 
(Qiagen, Valencia, CA, USA), according to the manufacturer’s 
instructions; the final elution volume of each sample was 200 μL. 
NPS specimens were vortexed briefly, and 500-μL aliquots of the 
3-mL samples of universal transport media were processed us-
ing NucliSens easyMAG Kits (bioMérieux, Marcy l’Etoile, France); 
the final elution volume of each sample was 50 μL.
3. Seeplex PneumoBacter ACE Detection Assay
This multiplex PCR kit can detect MP, CP, LP, Streptococcus 
pneumoniae (SP), Haemophilus influenzae (HI), and Bordetella 
pertussis (BP). The SP, HI, and BP data were not analyzed. PCR 
was performed in a total volume of 20 μL containing 3 μL of a 
DNA sample, 4 μL 5× PneumoBacter primer, 3 μL 8-methoxyp-
soralen, and 10 μL 2× Multiplex Master Mix, as per the manu-
facturer’s protocol. After heating at 94°C for 15 min, PCR reac-
tion mixutres underwent 40 cycles of amplification consisting of 
denaturation at 94°C for 0.5 min, annealing at 60°C for 1.5 min, 
and elongation at 72°C for 1.5 min. At the end of the last cycle, 
the final elongation step was extended for 10 min. Amplicons 
were visualized after agarose gel electrophoresis and GelRed 
staining (Biotium, Hayward, CA, USA). The estimated sizes of 
amplicon characteristic of MP, LP, and CP were 583 bp, 472 bp, 
and 146 bp, respectively. Each amplification reaction contained 
plasmid DNA as an internal control, and each run was accom-
panied by a positive control containing plasmids of the 6 target 
pathogens, and sterilized distilled water as a negative control. If 
the results of internal controls were negative, the PCR reaction 
was considered to have failed due to the presence of inhibitory 
substances. 
4. BD ProbeTec ET Atypical Pneumonia Assay 
APA uses a strand-displacement amplification technique to di-
rectly (qualitatively) detect DNA from MP, LP, and Chlamydia-
ceae in separate reactions. The manufacturer recommends the 
use of throat swabs or specimens from the lower respiratory 
tract for detection of MP and CP, and only specimens from the 
lower respiratory tract for detection of LP. We followed the man-
ufacturer’s instructions to perform the assay. Briefly, 150 μL of a 
DNA sample was placed in the priming well at room tempera-
ture for 20 min. The priming well was next heated to 72°C for 10 
min. One hundred microliters of sample was transferred to an 
amplification plate and incubated in the BD ProbeTec ET instru-Cho M-C, et al.
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ment for 1 hr. Amplification and detection were automatically 
performed by the instrument. One positive control and one neg-
ative control were included in each assay run. If the control re-
sults were not as expected, we considered the assay data to be 
invalid. 
 
5. Statistics
All statistical analyses were performed using SPSS version 13.0 
(SPSS, Inc., Chicago, IL, USA) and Excel 2007 (Microsoft, Red-
mond, WA, USA). We calculated agreement, sensitivity, specific-
ity, and 95% confidence intervals.
RESULTS
Both sputum and NPS specimens were available from 217 pa-
tients and we successfully performed the PneumoBacter assay 
on all samples. Some samples failed APA quality control criteria, 
resulting in 186 interpretable MP results, 206 interpretable LP 
results, and 204 interpretable CP results. 
  When the PneumoBacter assay was used to assess the 217 
sputum specimens, 20 (9.2%) were positive for MP and 2 (0.9%) 
were positive for LP. Using the APA assay, 21 (11.3%) samples 
were positive for MP and 2 (1.0%) were positive for LP (Fig. 1). 
Agreement between the PneumoBacter and APA data in detec-
tion of MP, LP, and CP was 99.5%, 100%, and 100%, respec-
tively. The kappa values were 0.97 for MP and 1.00 for both LP 
and CP (Table 1).
  There were only 8 (3.7%) samples positive for MP among the 
217 NPS samples. There were no NPS samples positive for LP. 
When results from the sputum and NPS samples were com-
bined, MP was detected in 21 patients. Seven of these 21 pa-
tients were positive in both sputum and NPS tests; 13 were spu-
tum-positive only, and 1 was NPS-positive only. Overall, sputum 
resulted in more PCR-positive (10.1% vs. 3.7%; Table 2). Com-
pared to APA, the sensitivity and specificity of sputum tests for 
MP were 95.2%, and 100.0%, respectively, and those of NPS 
were 38.1% and 93.9%, respectively. Sputum tests were more 
sensitive than NPS tests (P=0.002; Table 3). 
DISCUSSION
Our results reveal that specimen type is crucial for PCR-based 
diagnosis of MP and LP in CAP patients, and that sputum pro-
duces superior results than NPS. Throat swabs are the tradition-
ally preferred sample collection method for detection of MP [15]. 
However, the optimal sample type for molecular diagnosis re-
mains unclear [9, 12, 16-19]. In the studies evaluating specimen 
types for detection of serologically confirmed MP pneumonia, 
detection rates from sputum samples were higher than those 
from NPS samples or throat swabs (62.5% vs. 41.0% with nested 
Table 1. Comparison of BD ProbeTec ET Atypical Pneumonia As-
say and Seeplex PneumoBacter ACE Detection Assay results, using 
sputum specimens
Organism
Detection rate, %
(No. positive/No. valid tests) Agreement, % κ
APA PneumoBacter
M. pneumoniae 11.3 (21/186) 9.2 (20/217) 99.5 0.97
L. pneumophila 1.0 (2/206) 0.9 (2/217) 100.0 1.00
C. pneumoniae 0.0 (0/204) 0.0 (0/217) 100.0 1.00
Abbreviations: APA, BD ProbeTec ET Atypical Pneumonia Assay; Pneumo-
Bacter, Seeplex PneumoBacter ACE Detection assay; M. pneumoniae, My-
coplasma pneumoniae; L. pneumophila, Legionella pneumophila; C. pneu-
moniae, Chlamydophila pneumoniae. 
Table 2. Comparison of M. pneumoniae, L. pneumophila, and C. 
pneumoniae detection in sputum and NPS using the Seeplex Pneu-
moBacter ACE Detection Assay
Organism
Detection rate, %
(No. positive/No. valid tests) Total
Sputum NPS
M. pneumoniae  9.2 (20/217) 3.7 (8/217) 9.7 (21/217)
L. pneumophila 0.9 (2/217) 0.0 (0/217) 0.9 (2/217)
C. pneumoniae 0.0 (0/217) 0.0 (0/217) 0.0 (0/217)
Total  10.1 (22/217) 3.7 (8/217) 10.6 (23/217)
Abbreviations: NPS, nasopharyngeal swab M. pneumoniae, Mycoplasma 
pneumoniae; L. pneumophila, Legionella pneumophila; C. pneumoniae, 
Chlamydophila pneumoniae. 
Internal 
control
583 bp
472 bp
146 bp
M 1 2 3 4 5 6
Fig. 1. Results of the multiplex PCR Seeplex PneumoBacter ACE 
Detection Assay. Lane M, amplicon size marker. Bands of 583 bp, 
472 bp, and 146 bp are characteristic of Mycoplasma pneumoni-
ae, Legionella pneumophila, and Chlamydophila pneumoniae, re-
spectively. Lane 1, negative control; Lanes 2 and 3, nasopharyngeal 
swab (NPS) and sputum samples from an Mycoplasma pneumoni-
ae-positive patient; Lanes 4 and 5, NPS and sputum samples from 
a Legionella pneumophila-positive patient; Lane 6, positive control.Cho M-C, et al.
Specimens for molecular diagnosis of MP, CP, and LP
136 www.annlabmed.org http://dx.doi.org/10.3343/alm.2012.32.2.133
PCR [16] and 69.0% vs. 37.5% [9] with PCR-hybridization). 
  In an animal study, quantitative culture of MP resulted in a 
number of colony-forming units from lung samples 100-1,000 
times the number from throat samples [20]. MP was also more 
abundant in sputum than in upper respiratory tract (URT) sam-
ples in clinical specimens examined using nested PCR [21] and 
culture [22]. The higher number of MP organisms in pulmonary 
alveoli compared to the epithelium of the URT may explain the 
superiority of sputum samples for the MP tests in the present 
study. Compared to previous studies [9, 16], the sensitivity of 
tests using sputum samples were much higher than those using 
NPS in the present study. As only adult CAP patients were in-
cluded in this study, the difference in sensitivity between URT 
and lower respiratory tract specimens may be more pronounced 
than in the studies that included patients with both upper and 
lower respiratory tract infections of MP [9]. Indeed, British Tho-
racic Society Guidelines from 2009 recommend sputum for PCR 
detection of MP in CAP patients [4].
  The PneumoBacter assay had comparable sensitivity to APA 
when testing sputum samples. The 2 tests yielded near-perfect 
kappa values for MP and LP. However, we obtained valid results 
from all PneumoBacter sputum assays, whereas 14% of the APA 
sputum MP assays failed quality-control tests. PneumoBacter 
appears to be less vulnerable to defects in specimen quality. In a 
previous study using capillary PCR for analysis of throat swab, 
sputum, and bronchoalveolar lavage (BAL) samples, the lowest 
detection rate was from sputum samples (14.2%), compared to 
28.6% from throat swabs and 20.0% from BAL. However, the 
authors did not analyze specimens in parallel and did not control 
for the existence of PCR inhibitors. In the present study, DNA 
from sputum specimens was extracted by QIAamp DNA Stool 
Mini Kits that included a supplement for removing PCR inhibi-
tors. This helped to ensure valid results for all specimens in the 
PneumoBacter test. Thus, extraction methods yielding high-
quality DNA are also important for molecular testing [23]. 
  The difference in detection rates between sputum and URT 
samples in the present study was much larger than the differ-
ences reported previously [9, 16]. Efficient removal of PCR in-
hibitors can enhance the detection sensitivity in sputum speci-
mens and exaggerates the difference in sensitivity between spu-
tum and NPS samples. Flocked swabs collect more samples 
from patients than fibrous swabs [24]. While we used flocked 
swabs to obtain NPS samples, they were placed in universal 
transport medium. The effects of this medium on the results of 
molecular tests for MP, LP, and CP have not yet been evaluated. 
As this transport system may cause a dilution effect, the utility 
of NPS samples collected using flocked swabs for diagnosis of 
MP, CP, and LP requires further evaluation. Because 2 kinds of 
extraction kits were used in this study, the difference of sensitiv-
ity between types of specimen may result from extraction effi-
ciency. However, in a subsequent experiment, easyMAG was 
100 times more efficient for DNA extraction from sputum and 
1,000 times more efficient for extraction from NPS than QIAamp 
DNA Stool Mini Kit (data not shown). Even though we used an 
extraction method for sputum that was less efficient than for 
NPS, sputum assays had higher sensitivity than NPS assays.
  Only 2 sputum-positive LP samples were detected, and we 
found no CP-positive samples. Nucleic acid-based detection of 
Legionella spp. has been successful in sputum, urine, and blood 
specimens [25]. A few commercial assay kits are available, but 
only APA is approved by the U.S. Food and Drug Administration 
(FDA) [25]. The sensitivity of molecular tests has been estimated 
to be 80-100% when lower respiratory tract secretions are ana-
lyzed, and the specificity is estimated to be  >90% that of cul-
ture [26]. Throat swabs have been used for diagnosis of LP pneu-
monia in only a few studies [27, 28] and in a more recent study, 
the sensitivity of swab samples was inadequate to permit detec-
tion of LP [29]. We did not detect LP in any NPS samples, sup-
porting the preferred use of lower respiratory tract specimens 
for detection of LP. No optimal specimen type has been defined 
for diagnosis of CP infection. The clinical utility of nucleic acid-
based tests for CP is limited by the absence of a reliable gold 
standard method [30]. The sensitivities of sputum culture and 
PCR using sputum have been reported to be as high as 95% 
and 100%, respectively, compared to 35% and 30% for NPS 
samples [31]. The results of a previous study measuring the 
DNA levels in various respiratory specimens also supported the 
superiority of sputum for detection of CP by real-time PCR. In 
that study, sputum contained the highest concentration of CP 
(8.6×10
5 copies/mL) compared to 1.5×10
4 copies/mL in sam-
Table 3. Sensitivity and specificity of Seeplex PneumoBacter ACE 
Detection Assay compared to BD ProbeTec ET Atypical Pneumonia 
Assay when sputum samples were evaluated
Specimen types Organisms
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Sputum M. pneumonia 95.2 (90.2-99.8) 100.0 (NC)
L. pneumophila 100.0 (NC) 100.0 (NC)
NPS M. pneumonia 38.1 (17.1-59.1) 93.9 (90.2-97.6)
L. pneumophila 0.0 (NC) 100.0 (NC)
Abbreviations: M. pneumoniae, Mycoplasma pneumoniae; L. pneumophila, 
Legionella pneumophila; NPS, nasopharyngeal swab; CI, confidence inter-
val; NC, not calculated.Cho M-C, et al.
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ples from the nasopharynx and 3.1×10
3 copies/mL in throat 
samples [32]. Further studies using larger samples are required 
to evaluate molecular methods of LP and CP diagnosis. 
  In conclusion, the PneumoBacter assay for detection of MP, 
LP, and CP from sputum samples yielded the results compara-
ble to those from APA. Specimen type is crucial in molecular di-
agnosis, and sputum is preferred over NPS for simultaneous 
detection of MP, LP, and CP from CAP patients. 
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